Background. Increased synthesis and release of the potent bioactive peptide
endothelin-l (ET-1) occurs during and after cardiac surgery. However, the
cellular and molecular basis for the effects of ET-1 on human left ventricu
lar (LV) myocyte contractility remains unknown.
Methods. LV myocyte contractility was examined from myocardial biopsies tak
en from patients (n = 30) undergoing elective coronary artery bypass. LV my
ocytes (n = 997, > 30/patient) were isolated using microtrituration and con
tractility examined by videomicroscopy at baseline and after ET-1 exposure
(200 pmol/L). In additional studies, myocytes were pretreated to inhibit ei
ther protein kinase C (PKC) (chelerythrine, 1 mu mol/L), the sodium/hydroge
n (Na/H) exchanger (EIPA, 1 mu mol/L), both PKC and the Na/H exchanger, or
the ETA receptor (BQ-123, 1 mu mol/L), followed with ET-1 exposure.
Results. Basal myocyte shortening increased 37.8 +/- 6.3% with ET-1 (p < 0.
05). Na/H exchanger, PKC, and dual inhibition all eliminated the effects of
ET-1. Furthermore, ETA inhibition demonstrated that ET-1 effects on myocyt
e contractility were mediated through the ETA receptor subtype.
Conclusions. ET-1 directly influences human LV myocyte contractility, which
is mediated through the ETA receptor and requires intracellular activation
of PKC and stimulation of the Na/H exchanger. (C) 2000 by The Society of T
horacic Surgeons.